The good, the bad and the ugly: A tale of miR-101, miR-21 and miR-155 in pancreatic intraductal papillary mucinous neoplasms

Annals of Oncology

Volumn 24, Issue 3, 2013, Pages 734-741

  Caponi, S ^a   Funel, N ^b   Frampton, A E ^c   Mosca, F ^a   Santarpia, L ^d   Van der Velde, A G ^e   Jiao, L R ^c   De Lio, N ^a   Falcone, A ^a   Kazemier, G ^e   Meijer, G A ^e   Verheul, H M ^e   Vasile, E ^a   Peters, G J ^e   Boggi, U ^a   Giovannetti, E ^e  

^a UNIVERSITY HOSPITAL OF PISA   (Italy)

^b UNIVERSITY OF PISA   (Italy)

^c IMPERIAL COLLEGE LONDON   (United Kingdom)

^d Hospital of Prato   (Italy)

^e VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

MicroRNA 101; MicroRNA 155; MicroRNA 21; Outcome; Pancreatic intraductal papillary mucinous neoplasms

Indexed keywords

BIOLOGICAL MARKER; MICRORNA; MICRORNA 101; MICRORNA 21; MICRORNA 55; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CONFIDENCE INTERVAL; CONTROLLED STUDY; DISEASE FREE SURVIVAL; FEMALE; GENE EXPRESSION; HAZARD RATIO; HUMAN; HUMAN TISSUE; INTRADUCTAL PAPILLARY MUCINOUS TUMOR; LASER MICRODISSECTION; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGNOSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TUMOR GROWTH; UNIVARIATE ANALYSIS; UPREGULATION;

ADENOCARCINOMA, MUCINOUS; ADENOCARCINOMA, PAPILLARY; ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, PANCREATIC DUCTAL; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; LYMPHATIC METASTASIS; MALE; MICRORNAS; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOPLASM INVASIVENESS; PANCREATIC NEOPLASMS; PROPORTIONAL HAZARDS MODELS;

EID: 84874562085     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mds513     Document Type: Article

References (50)

1. Ohhashi KMY, Takekoshi T. Four cases of mucin producing cancer of the pancreas on specific findings of papilla of Vater. Prog Diagn Endosc 1982; 20: 348-351.
2. Zamboni G, Klöppel G, Hruban RH et al. Mucinous cystic neoplasms of the pancreas. In Hamilton SR, Aaltonen LA (eds), Pathology and Genetics of Tumours of the Digestive System. WHO Classification of Tumours. Lyon, France: IARC Press 2000; 234-236.
3. Andrejevic-Blant S, Kosmahl M, Sipos B et al.. Pancreatic intraductal papillarymucinous neoplasms: a new and evolving entity. Virchows Arch 2007; 451: 863-869.
4. Kosmahl M, Pauser U, Peters K et al.. Cystic neoplasms of the pancreas and tumor-like lesions with cystic features: a review of 418 cases and a classification proposal. Virchows Arch 2004; 445: 168-178.
5. Longnecker DS, Adler G, Hruban RH et al. Intraductal papillary-mucinous neoplasms of the pancreas. In Hamilton SR, Aaltonen LA (eds), World Health Organization Classification of Tumors. Lyon, France: IARC Press 2000; 237-241.
6. Salvia R, Fernández-del Castillo C, Bassi C et al.. Main duct intraductal papillarymucinous neoplasms of the pancreas: clinical predictors of malignancy and long term survival following resection. Ann Surg 2004; 239: 678-685.
7. Sohn TA, Yeo CJ, Cameron JL et al.. Intraductal papillary-mucinous neoplasms of the pancreas: an update experience. Ann Surg 2004; 239: 788-797.
8. Nagai K, Doi R, Kida A et al.. Intraductal papillary mucinous neoplasms of the pancreas: clinicopathologic characteristics and long-term follow-up after resection. World J Surg 2008; 32: 271-278.
9. Niedergethmann M, Grützmann R, Hildenbrand R et al.. Outcome of invasive and noninvasive intraductal papillary-mucinous neoplasms of the pancreas (IPMN): a 10-year experience. World J Surg 2008; 32: 2253-2260.
10. Wada K, Kozaked RA, Traverso LW. Outcomes following resection of invasive and noninvasive intraductal papillary mucinous neoplasm of the pancreas. Am J Surg 2005; 189: 632-637.
11. Wasif N, Bentrem DJ, Farrell JJ et al.. Invasive intraductal papillary mucinous neoplasm versus sporadic pancreatic adenocarcinoma. Cancer 2010; 116: 3369-3377.
12. Murakami Y, Uemura K, Sudo T et al.. Invasive intraductal papillary-mucinous neoplasm of the pancreas: comparison with pancreatic ductal adenocarcinoma. J Surg Oncol 2009; 100: 13-18.
13. Waters JA, Schnelldorfer T, Aguilar-Saavedra JR et al.. Survival after resection for invasive intraductal papillary mucinous neoplasm and for pancreatic adenocarcinoma: a multi-institutional comparison according to American Joint Committee on Cancer Stage. J Am Coll Surg 2011; 213: 275-283.
14. Neoptolemos JP, Stocken DD, Friess H et al.. A randomized trial of chemoradiotherapy and chemotherapy after resection of pancreatic cancer. N Engl J Med 2004; 350: 1200-1210.
15. Neoptolemos JP, Stocken DD, Bassi C et al.. Adjuvant chemotherapy with fluorouracil plus folinic acid vs gemcitabine following pancreatic cancer resection. JAMA 2010; 304: 1073-1081.
16. Caponi S, Vasile E, Del Chiaro M et al. Prognostic relevance of lymph node metastases and adjuvant treatment for patients with invasive intraductal papillary mucinous neoplasms (IPMNs) of the pancreas. In 2010 ASCO Gastrointestinal Cancers Symposium. Orlando, Florida. 22 January 2010 Abstract 252.
17. Siveke JT, Einwächter H, Sipos B et al.. Concomitant pancreatic activation of Kras (G12D) and Tgfa results in cystic papillary neoplasms reminiscent of human IPMN. Cancer Cell 2007; 12: 266-279.
18. Sato N, Matsubayashi H, Abe T et al.. Epigenetic down-regulation of CDKN1C/ p57KIP2 in pancreatic ductal neoplasms identified by gene expression profiling. Clin Cancer Res 2005; 11: 4681-4688.
19. Lu J, Getz G, Miska EA et al.. MicroRNA expression profiles classify human cancers. Nature 2005; 435: 834-838.
20. Giovannetti E, Erozenci A, Smit J et al.. Molecular mechanisms underlying the role of microRNAs (miRNAs) in anticancer drug resistance and implications for clinical practice. Crit Rev Oncol Hematol 2012; 81: 103-122.
21. Giovannetti E, Funel N, Peters GJ et al.. MicroRNA-21 in pancreatic cancer: correlation with clinical outcome and pharmacologic aspects underlying its role in the modulation of gemcitabine activity. Cancer Res 2010; 70: 4528-4538.
22. Hwang JH, Voortman J, Giovannetti E et al.. Identification of microRNA-21 as a biomarker for chemoresistance and clinical outcome following adjuvant therapy in resectable pancreatic cancer. PLoS One 2010; 5: e10630.
23. Bloomston M, Frankel WL, Petrocca F et al.. MicroRNA expression patterns to differentiate pancreatic adenocarcinoma from normal pancreas and chronic pancreatitis. JAMA 2007; 297: 1901-1908.
24. Lee EJ, Gusev Y, Jiang J et al.. Expression profiling identifies microRNA signature in pancreatic cancer. Int J Cancer 2006; 120: 1046-1054.
25. Szafranska AE, Doleshal M, Edmunds HS et al.. Analysis of microRNAs in pancreatic fine-needle aspirates can classify benign and malignant tissues. Clin Chem 2008; 54: 1716-1724.
26. Habbe N, Koorstra JB, Mendell JT et al.. MicroRNA miR-155 is a biomarker of early pancreatic neoplasia. Cancer Biol Ther 2009; 8: 340-346.
27. Ryu JK, Matthaei H, Dal Molin M et al.. Elevated microRNA miR-21 levels in pancreatic cyst fluid are predictive of mucinous precursor lesions of ductal adenocarcinoma. Pancreatology 2011; 11: 343-350.
28. Nakahara O, Takamori H, Iwatsuki M et al. Carcinogenesis of intraductal papillary mucinous neoplasm of the pancreas: loss of microRNA-101 promotes overexpression of histone methyltransferase EZH2. Ann Surg Oncol 2011; 19 Suppl 3: 565-571.
29. Funel N, Giovannetti E, Pollina LE et al.. Critical role of laser microdissection for genetic, epigenetic and proteomic analyses in pancreatic cancer. Expert Rev Mol Diagn 2011; 11: 695-701.
30. Fernández-del Castillo C, Adsay NV. Intraductal papillary mucinous neoplasms of the pancreas. Gastroenterology 2010; 139: 708-713.
31. Shi C, Hruban RH. Intraductal papillary mucinous neoplasm. Hum Pathol 2012; 43: 1-16.
32. Wu J, Matthaei H, Maitra A et al.. Recurrent GNAS mutations define an unexpected pathway for pancreatic cyst development. Sci Transl Med 2011; 3: 92ra66.
33. Furukawa T, Kuboki Y, Tanji E et al. Whole-exome sequencing uncovers frequent GNAS mutations in intraductal papillary mucinous neoplasms of the pancreas. Sci Rep 2011; 1: 161.
34. D'Angelica M, Brennan MF, Suriawinata AA et al.. Intraductal papillary mucinous neoplasms of the pancreas: an analysis of clinicopathologic features and outcome. Ann Surg 2004; 239: 400-408.
35. Jang JY, Hwang DW, Kim MA et al.. Analysis of prognostic factors and a proposed new classification for invasive papillary mucinous neoplasms. Ann Surg Oncol 2011; 18: 644-650.
36. Swartz MJ, Hsu CC, Pawlik TM et al.. Adjuvant chemoradiotherapy after pancreatic resection for invasive carcinoma associated with intraductal papillary mucinous neoplasm of the pancreas. Int J Radiat Oncol Biol Phys 2010; 76: 839-844.
37. Moriyama T, Ohuchida K, Mizumoto K et al.. MicroRNA-21 modulates biological functions of pancreatic cancer cells including their proliferation, invasion, and chemoresistance. Mol Cancer Ther 2009; 8: 1067-1074.
38. Gironella M, Seux M, Xie MJ et al.. Tumor protein 53-induced nuclear protein 1 expression is repressed by miR-155, and its restoration inhibits pancreatic tumor development. Proc Natl Acad Sci USA 2007; 104: 16170-16175.
39. Ougolkov AV, Bilim VN, Billadeau DD. Regulation of pancreatic tumor cell proliferation and chemoresistance by the histone methyltransferase enhancer of zeste homologue 2. Clin Cancer Res 2008; 14: 6790-6796.
40. Jamieson NB, Morran DC, Morton JP et al.. MicroRNA molecular profiles associated with diagnosis, clinicopathological criteria, and overall survival in patients with resectable pancreatic ductal adenocarcinoma. Clin Cancer Res 2012; 18: 534-545.
41. Greither T, Grochola LF, Udelnow A et al.. Elevated expression of microRNAs 155, 203, 210 and 222 in pancreatic tumors is associated with poorer survival. Int J Cancer 2010; 126: 73-80.
42. Toll AD, Dasgupta A, Potoczek M et al.. Implications of enhancer of zeste homologue 2 expression in pancreatic ductal adenocarcinoma. Hum Pathol 2010; 41: 1205-1209.
43. Fu X, Han Y, Wu Y et al.. Prognostic role of microRNA-21 in various carcinomas: a systematic review and meta-analysis. Eur J Clin Invest 2011; 41: 1245-1253.
44. Medina PP, Nolde M, Slack FJ. OncomiR addiction in an in vivo model of microRNA-21-induced pre-B-cell lymphoma. Nature 2010; 467: 86-90.
45. Meng F, Henson R, Lang M et al.. Involvement of human micro-RNA in growth and response to chemotherapy in human cholangiocarcinoma cell lines. Gastroenterology 2006; 130: 2113-2129.
46. Blower PE, Chung JH, Verducci JS et al.. MicroRNAs modulate the chemosensitivity of tumor cells. Mol Cancer Ther 2008; 7: 1-9.
47. Park JK, Lee EJ, Esau C et al. Antisense inhibition of microRNA-21 or -221 arrests cell cycle, induces apoptosis, and sensitizes the effects of gemcitabine in pancreatic adenocarcinoma. Pancreas 2009; 38: e190-e199.
48. Stingl Kirchheiner JC, Brockmöller J. Why, when, and how should pharmacogenetics be applied in clinical studies? Current and future approaches to study designs. Clin Pharmacol Ther 2011; 89: 198-209.
49. Matthaei H, Wylie D, Lloyd MB et al. MicroRNA biomarkers in cyst fluid augment the diagnosis and management of pancreatic cysts. Clin Cancer Res 2012; 18: 4713-4724.
50. Jang JY, Kim SW, Lee SE et al.. Treatment guidelines for branch duct type intraductal papillary mucinous neoplasms of the pancreas: when can we operate or observe? Ann Surg Oncol 2008; 15: 199-205.